Article
CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk.
British journal of cancer - 19 Jan 2016
Garcia-Albeniz Xabier, Rudolph Anja, Hutter Carolyn, White Emily, Lin Yi, Rosse Stephanie A, Figueiredo Jane C, Harrison Tabitha A, Jiao Shuo, Brenner Hermann, Casey Graham, Hudson Thomas J, Thornquist Mark, Le Marchand Loic, Potter John, Slattery Martha L, Zanke Brent, Baron John A, Caan Bette J, Chanock Stephen J, Berndt Sonja I, Stelling Deanna, Fuchs Charles S, Hoffmeister Michael, Butterbach Katja, Du Mengmeng, James Gauderman W, Gunter Marc J, Lemire Mathieu, Ogino Shuji, Lin Jennifer, Hayes Richard B, Haile Robert W, Schoen Robert E, Warnick Greg S, Jenkins Mark A, Thibodeau Stephen N, Schumacher Fredrick R, Lindor Noralane M, Kolonel Laurence N, Hopper John L, Gong Jian, Seminara Daniela, Pflugeisen Bethann M, Ulrich Cornelia M, Qu Conghui, Duggan David, Cotterchio Michelle, Campbell Peter T, Carlson Christopher S, Newcomb Polly A, Giovannucci Edward, Hsu Li, Chan Andrew T, Peters Ulrike, Chang-Claude Jenny
Abstract excerpt
BACKGROUND: Menopausal hormone therapy (MHT) use has been consistently associated with a decreased risk of colorectal cancer (CRC) in women. Our aim was to use a genome-wide gene-environment interaction analysis to identify genetic modifiers of CRC risk associated with use of MHT. METHODS: We included 10 835 postmenopausal women (5419 cases and 5416 controls) from 10 studies. We evaluated use of any MHT,...
Read the complete abstract on PubMed